Company: GIFLF
Filing Date: 2025-02-26
Form Type: 6-K
Source: 0001104659-25-017501
Chunk: 0

Company: Grifols SA
Filing Date: 2025-02-26
Form: 6-K
Chunk 0
---
<div align='center'>UNITED STATES
SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

Form 6-K

REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934

For the month of February 2025

Commission File No. 001-35193

Grifols, S.A.

(Translation of registrant’s name into English)

Avinguda de la Generalitat, 152-158

Parc de Negocis Can Sant Joan

Sant Cugat del Valles 08174

Barcelona, Spain

(Address of registrant’s principal executive
office)</div>

Indicate by check mark whether the registrant files or will file annual
reports under cover Form 20-F or Form 40-F.

| Form 20-F | x |     | Form 40-F | ¨ |

<div align='center'>Grifols, S.A.

TABLE OF CONTENTS</div>

| Item 
 1.   
 2.   | Press Release,                            
 dated February 26, 2025                   
 Q4 2024 Earnings Presentation             |     | Sequential Page Number 
                      3 
                      7 |
|:-----|:------------------------------------------|:----|-----------------------:|
| 3.   | Consolidated Audited Financial Statements |     |                     51 |

Fourth Quarter and Year End 2024 Results

Grifols delivers a strong 2024 exceeding guidance on revenue and free cash flow

| · | Revenue                                                                                
 reached EUR 1,976 million in the fourth quarter (+13.6% at cc1) driven by Biopharma’s  
 growth of 15.1% at cc. FY24 revenue reports EUR 7,212 million, a 10.3% at cc increase. |

| · | Adjusted                                                                                  
 EBITDA increased by 19% to EUR 526 million (26.6% margin) in Q4’24, driving Adjusted      
 EBITDA for FY24 to EUR 1,779 million (24.7% margin). Reported EBITDA increased by +32% up 
 to EUR 1,631 million for FY24.                                                            |

| · | Net                                                                                      
 profit improved in Q4, reaching EUR 69 million and bringing the full-year 2024 result to 
 EUR 157 million, an